Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex Pharmaceuticals (NASDAQ ... offering patients a strong safety profile. The U.S. Food and Drug Administration (FDA) approved the drug for use in acute pain, but Vertex aims to eventually ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

“There's a huge need for additional research and development on pain management,” said Paul Howe, chief commercial officer for Protega Pharmaceuticals ... Vertex advance new types of pain ...

Vertex Pharmaceuticals (NASDAQ ... which could limit the drug's accessibility. Moreover, if chronic pain indications are pursued in the future, significant price reductions may be necessary ...

Vertex Pharma's non-opioid painkiller suzetrigine ... that the study was not powered to show a difference between the drug and placebo – shares fell by more than 12% as investors reacted to ...

or dizziness – and AP-325 had a placebo-like safety profile, according to Algiax. The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx ...